GANX: Gain Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
50 institutions reported holding $14.93M of Gain Therapeutics, Inc. on Form 13F (42 the quarter before). 12 opened a new position and 4 sold out. Shares held by institutions: +2%.
| Largest holders | Shares | Value |
|---|---|---|
| MARSHALL WACE, LLP | 1,923,546 | $3.90M |
| Potomac Capital Management, Inc. | 946,400 | $1.92M |
| DME Capital Management, LP | 566,130 | $1.15M |
| JONES FINANCIAL COMPANIES LLLP | 608,592 | $1.07M |
| VANGUARD CAPITAL MANAGEMENT LLC | 480,269 | $975K |
| GEODE CAPITAL MANAGEMENT, LLC | 453,501 | $921K |
| BlackRock, Inc. | 274,957 | $558K |
| VANGUARD FIDUCIARY TRUST CO | 231,534 | $470K |
| UBS Group AG | 215,012 | $436K |
| Stratos Wealth Partners, LTD. | 200,000 | $406K |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.